Aurobindo Pharma to buy some commercial products from Teva
26 Nov 2016
Hyderabad-based Aurobindo Pharma Ltd yesterday struck a deal to buy some commercial products in France from Israeli generic drug giant Teva Pharmaceuticals for an undisclosed sum.
Arrow Generiques SAS, the French subsidiary of the company "will acquire the right, title and interest in products Calcium and Calcium Vitamin D3, including the use of the Orocal trademark from Teva," Aurobindo Pharma said in a statement.
The transaction is subject to the approval of the European Commission.
Post closing, Arrow Generiques will integrate these products with its existing commercial operations in France and both Arrow Generiques and Teva intend to ensure continuity of the supply of the products to the market.
The acquisition will enable Arrow Generiques to continue to increase its branded products portfolio and leverage its position as a key player in the drug market.
Arrow Generiques is a pharmaceutical company with focus on selling generics on the retail and hospital markets in France since 2002.
The company has a growing portfolio of around 800 generic pharmaceuticals, and several brand medications.
Among the largest vertically integrated pharmaceutical companies in India, Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.
The company's product portfolio is spread over six major therapeutic / product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, and anti-allergics.
Its manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK's MHRA, Japan's PMDA, WHO, Health Canada, MCC of South Africa and ANVISA of Brazil.
The company markets its products in over 125 countries and has an annual turnover of around $1.8 billion.
